Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

Chest

Volumn 126, Issue 1 SUPPL., 2004, Pages 78S-92S

  McLaughlin, Vallerie V ^a   Presberg, Kenneth W ^b   Doyle, Ramona L ^c   Abman, Steven H ^d   McCrory, Douglas C ^e   Fortin, Terry ^e   Ahearn, Gregory ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

6 min walk test; Cardiopulmonary exercise testing; Echocardiography; Epoprostenol; Functional class; Hemodynamics; Prognosis; Pulmonary hypertension; Survival; Vasoreactivity

Indexed keywords

ADOLESCENT; ADULT; CONTROLLED STUDY; DISEASE COURSE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SCHOOL CHILD; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 3142777629     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.1_suppl.78S     Document Type: Article

References (45)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349
2. Sandoval J, Bauerele O, Palomar A, et al. Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994; 89:1733-1744
3. Okada O, Tanabe N, Yasuda J, et al. Prediction of life expectancy in patients with primary pulmonary hypertension: a retrospective nationwide survey from 1980-1990. Intern Med 1999; 38:12-16
4. Rajasekhar D, Balakrishnan KG, Venkitachalam CG, et al. Primary pulmonary hypertension: natural history and prognostic factors. Indian Heart J 1994; 46:165-170
5. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29:515-524
6. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167:580-586
7. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123:344-350
8. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case control study; Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155:990-995
9. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994; 89:2722-2727
10. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100-105
11. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409-415
12. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
13. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. Am Coll Cardiol 1997; 30:343-349
14. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. Am Coll Cardiol 2002; 40:780-788
15. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
16. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425-434
17. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1188-1192
18. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-587
19. Rich S, Kaufmann E, Lew PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81
20. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112:714-721
21. Sondheimer HM, Lung MC, Brugman SM, et al. Pulmonary vascular disorders masquerading as interstitial lung disease. Pediatr Pulmonol 1995; 20:284-288
22. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865
23. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for PPH in children. Circulation 1999; 99:1197-1208
24. Sandoval J, Bauerle O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995; 25:466-474
25. Appelbaum L, Yigla M, Bendayan D, et al. Primary pulmonary hypertension in Israel: a national survey. Chest 2001; 119:1801-1806
26. Chun KJ, Kim SH, An BJ, et al. Survival and prognostic factors in patients with primary pulmonary hypertension. Korean J Intern Med 2001; 16:75-79
27. Glanville AR, Burke CM, Theodore J, et al. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest 1987; 91:675-681
28. Conte JV, Gaine SP, Orens JB, et al. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998; 17:679-685
29. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39:1214-1219
30. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93:484-488
31. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80:151-155
32. Eysmann SB, Palevsky HI, Reichek N, et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989; 80:353-360
33. Hinderliter AL, Willis PW 4th, Long W, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Am J Cardiol 1999; 84:481-484,A10
34. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996; 9:838-847
35. Yeo TC, Dujardin KS, Tei C, et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81:1157-1161
36. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492
37. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106:319-324
38. Paciocco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17:647-652
39. Bossone E, Paciocco G, Iarussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002; 121:513-518
40. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160:487-492
41. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-870
42. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension; relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26:1581-1585
43. Fox AC, Reed GE, Meilman H, et al. Release of nucleosides from canine and human hearts as an index of prior ischemia. Am J Cardiol 1979; 3:52-58
44. Mentzer RM, Rubio R, Berne RM. Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. Am J Physiol 1975; 229:1625-1631
45. Lopes AA, Maeda NY, Goncalves RC, et al. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J 2000; 139:618-623